Pluri Company Description

Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and cell-based technologies for various industries.

It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and a novel immunotherapy platform.

The company’s product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to COVID-19, peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, is composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and phase I trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform.

It also offers cell manufacturing services; cell-based coffee; and develops and commercializes cultivated meat products.

The company operates in the field of regenerative medicine, food-tech, CDMO, and agtech. It has collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors.

The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022.

Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Pluri Inc.

Country	United States
Founded	2001
Industry	Biotechnology
Sector	Healthcare
Employees	118
CEO	Yaacov Yanay

Contact Details

Address: Building No. 5 Haifa, Nevada 3508409 Israel
Phone	972 74 710 8600
Website	pluri-biotech.com

Stock Details

Ticker Symbol	PLUR
Exchange	Tel Aviv Stock Exchange
Stock Type	Common Stock
Fiscal Year	July - June
Reporting Currency	USD
ISIN Number	US72942G2030
SIC Code	2836

Key Executives

Name	Position
Yaacov Yanay	Chief Executive Officer
Liat Zalts	Chief Financial Officer